Skip to content

Towards a Sex-specific Female Enhanced Recovery After Cardiac Surgery'' (F-ERAS) Pathway:

Towards a Sex-specific Female Enhanced Recovery After Cardiac Surgery'' (F-ERAS) Pathway: An Observational Registration and Evaluation of Characteristics and Perioperative Management of Cardiac Surgery Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06175650
Acronym
F-ERAS
Enrollment
5500
Registered
2023-12-19
Start date
2023-11-21
Completion date
2026-11-21
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female, Male, Surgery,Cardiac

Keywords

Anesthesia, Quality of Life

Brief summary

The aim of this study is to evaluate the differences between men and women undergoing cardiac surgery. We will look at perioperative factors such as body weight, body surface area, previous medical history, pharmacokinetics, transfusion, coagulation, cardiopulmonary bypass (CPB) related factors, cardiac function, inotropic requirements, risk, and outcome scores as well as morbidity and mortality at 30 and 90 days, 1, 5, and 10 years.

Detailed description

Observational, multicentre, retrospective data collection from the mandatory Quality Assurance database (the Netherlands Heart Registry, (NHR), supplemented with data from the electronic patient files (EPIC). The retrospective data is already available. In addition, we will continue the retrospective study into a prospective registry of data after the analysis of the retrospective data. Patients will be approached one, five and ten years after the operation and a questionnaire will be sent to document quality of life. No research-related interventions other than questionnaires will be performed

Interventions

PROCEDURECardiac surgery

Cardiac surgery of all types

Sponsors

Jennifer Breel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients \> 18 years * All patients who underwent cardiac surgery from 1 January 2016 to the start of the study, in either of the centres (AMC or VUmc) (retrospective) * All patients undergoing cardiac surgery from the start of the study (\ March 2022) until approximately 2032

Exclusion criteria

• Patients who object to the re-use of their care data or do not give consent

Design outcomes

Primary

MeasureTime frameDescription
Primary endpointup to 30 days post-surgeryIncidence of mortality (number of patients) specific (coagulation), transfusion products, anesthesia, surgery and cross-clamp times, etc
Primary outcomeup to 30 days post-surgery or if still in hospital, until dischargeTimes: surgical, cross-clamp, bypass, anesthetic, intensive care admission, hospital admission, etc.

Secondary

MeasureTime frameDescription
Morbidity and mortalityAt 30, 90, 365 daysperoperative and post-operative complications
SurvivalAt 5 and 10 yearsLong term survival
Health related Quality of life measured by PROMSAt 1, 5 and 10 yearsLong term quality of life after cardiac surgery, measured by Seattle Angina Questionaire (SAQ), EuroQol Quality of life (EQ-5D-5L) and Coronary Revascularisation Outcome Questionnaire (CROQ) or other appropriate questionnaire

Countries

Netherlands

Contacts

Primary ContactJennifer S Breel, MSc
j.s.breel@amsterdamumc.nl+31610019257
Backup ContactSusanne Eberl, PhD
s.eberl@amsterdamumc.nl+31610019257

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026